HKD 6.95
(0.14%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 137.62 Million CNY | 1110.83% |
2022 | 11.36 Million CNY | 457.7% |
2021 | 2.03 Million CNY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 47.78 Million CNY | 0.0% |
2024 Q1 | 47.78 Million CNY | -7.46% |
2023 Q4 | 51.64 Million CNY | 0.0% |
2023 Q3 | 51.64 Million CNY | 200.73% |
2023 FY | 137.62 Million CNY | 1110.83% |
2023 Q2 | 17.17 Million CNY | 0.0% |
2023 Q1 | 17.17 Million CNY | 220.72% |
2022 FY | 11.36 Million CNY | 457.7% |
2022 Q4 | 5.35 Million CNY | 0.0% |
2022 Q3 | 5.35 Million CNY | 0.0% |
2021 FY | 2.03 Million CNY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Uni-Bio Science Group Limited | 484.71 Million HKD | 71.608% |
CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 97.414% |